COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM

被引：0
|
作者：
Fievez, S. [1 ]
Blanc, E. [1 ]
Bougeois, M. [1 ]
Sivignon, M. [2 ]
Supiot, R. [3 ]
Vietri, J. [4 ]
Perdrizet, J. [4 ]
Bellier, L. [3 ]
机构：
[1] Pfizer SAS France, Paris, France
[2] Putnam PHMR, Lyon, France
[3] Putnam PHMR, Paris, France
[4] Pfizer Inc, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL VACCINATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPSV23) ON ADULT POPULATION IN SOUTH KOREA
    Park, D.
    Kang, S.
    VALUE IN HEALTH, 2017, 20 (09) : A788 - A788
  • [22] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN COLOMBIA
    Nunez, S. M.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Roberts, C. S.
    La Rotta, J. E.
    VALUE IN HEALTH, 2012, 15 (04) : A242 - A242
  • [23] Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands
    de Vries, L. M.
    Kellerborg, K. M.
    Brouwer, W. B. F.
    van Baal, P. H. M.
    VACCINE, 2021, 39 (29) : 3834 - 3843
  • [24] COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN COLOMBIA
    Coronel, W.
    Jaramillo, J.
    Caceres, H. A.
    Riveros, L.
    VALUE IN HEALTH, 2011, 14 (03) : A117 - A117
  • [25] Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis
    Ta, An
    Kuehne, Felicitas
    Laurenz, Maren
    von Eiff, Christof
    Warren, Sophie
    Perdrizet, Johnna
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (06) : 1333 - 1358
  • [26] COST-EFFECTIVENESS ANALYSIS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV20) TO PREVENT PNEUMOCOCCAL DISEASE IN THE GREEK PEDIATRIC POPULATION
    Tzanetakos, C.
    Kokkinaki, I
    Barmpouni, M.
    Kossyvaki, V
    Psarra, M.
    Perdrizet, J.
    Gourzoulidis, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [27] Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection
    Marbaix, Sophie
    Peetermans, Willy E.
    Verhaegen, Jan
    Annemans, Lieven
    Sato, Reiko
    Mignon, Annick
    Atwood, Mark
    Weycker, Derek
    PLOS ONE, 2018, 13 (07):
  • [28] The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
    Feldman, Charles
    Dlamini, Sipho K.
    Madhi, Shabir A.
    Meiring, Susan
    von Gottberg, Anne
    de Beer, Janetta C.
    de Necker, Margreet
    Stander, Marthinus P.
    PLOS ONE, 2020, 15 (01):
  • [29] COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN BOGOTA, COLOMBIA
    Torres, C.
    Jaramillo, J.
    Coronell, W.
    Gutierrez, M., V
    Caceres, H. A.
    VALUE IN HEALTH, 2011, 14 (07) : A538 - A538
  • [30] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
    Olsen, Jens
    Schnack, Henrik
    Skovdal, Mette
    Vietri, Jeffrey
    Mikkelsen, Malene Buch
    Poulsen, Peter Bo
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1240 - 1254
12345